Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA, RSV and Pfizer
FDA expands Pfizer’s RSV vaccine label to include all high-risk adults
The US Food and Drug Administration (FDA) has expanded the indication for Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo to include adults aged 18–59 years who have chronic conditions that place them at increased risk of lower respiratory tract disease caused by the virus.
FDA approves Pfizer's RSV shot Abrysvo for all at-risk adults
While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to determine how much advantage will be gained from the nod as the Centers for Disease Control (CDC) will have to sign off on Abvrysvo's use in the wider age group.
Pfizer gets a leg up in RSV as FDA clears jab for all adults
A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival shots from GSK and Moderna, but it may not make much of a difference in the battle for market share.
FDA Approves Pfizer's Respiratory Syncytial Virus Vaccine Abrysvo For Adults Below 60 Years
Abrysvo (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, to prevent lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 who are at high risk.
Pfizer Wins FDA Approval of RSV Vaccine for Broader Adult Population
Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age. Tuesday’s label expansion covers younger adults who are deemed at higher risk of RSV-related lower respiratory tract disease.
US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease.
Pfizer’s RSV vaccine cleared by FDA for use in some younger adults
Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will expand the number of people eligible for vaccination with the shot.
FDA Approves Abrysvo RSV Vaccine for Adults at Increased Risk
Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.
New FDA approval for Pfizer’s RSV vaccine Abrysvo
The US Food and Drug Administration (FDA) yesterday approved Abrysvo (respiratory syncytial virus vaccine). Developed and marketed by US pharma giant Pfizer, the vaccine is now authorized for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV.
FDA Expands Approval of RSV Vaccine Abrysvo to Include All At-Risk Adults
The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in high-risk adults ages 18 to 59 years, Pfizer announced on Tuesday.
FDA Okays Pfizer's RSV Vaccine ABRYSVO For Adults Aged 18 To 59 At Increased Risk For Disease
Pfizer Inc. (PFE) announced that the U.S. Food and Drug Administration approved ABRYSVO (Respiratory Syncytial Virus Vaccine), the
McKnight's Long-Term Care News
1d
FDA OKs Pfizer’s RSV vaccine for some adults under 60
On Tuesday, the US Food and Drug Administration (FDA) approved
Pfizer
’s respiratory syncytial virus (RSV) vaccine,
Abrysvo
, for people 18 to 59 who are more vulnerable to the virus.
Pfizer
’s ...
1d
Is Pfizer's Attractive Valuation Enough to Invest in the Stock?
PFE's non-COVID drugs and potential contributions from new and newly acquired products have started to drive growth.
1d
Mixed Prospects and Uncertainty Lead to Hold Rating for Pfizer Amid COVID-19 Revenue Fluctuations
Analyst Mohit Bansal from Wells Fargo maintained a Hold rating on Pfizer (PFE – Research Report) and keeping the price target at $30.00.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
Workers reject new contract
NK troops in RU confirmed
Settles civil lawsuit
Linked to E. coli outbreak
Suffers 'debilitating' stroke
Joins Republican Party
'Tarzan' star Ron Ely dies
Biden says lock up Trump
Closing argument speech plan
Yelp disables reviews
Trespassing charge upheld
FDA recalls antidepressant
Kentucky lawmaker dies
Boeing satellite explodes
First father-son duo in NBA
Veteran film producer dies
Hashem Safieddine killed
US fines American Airlines
Sues Biden administration
Dodgers legend dies
Lake Erie toxic algae study
Giant ‘ghost’ fish spotted
FAA finalizes safety rules
To close 150 locations
MO court upholds release
DOJ alleges racial bias
Bird flu infects 4 in WA
GA election rules appeal
Timberlake postpones shows
G7 Ukraine loan advances
Israel strikes Lebanese city
DNC office shootings arrest
Feedback